Free Trial

Evotec (ETR:EVT) Trading Down 3.4% - Here's What Happened

Evotec logo with Medical background

Evotec SE (ETR:EVT - Get Free Report) fell 3.4% during mid-day trading on Thursday . The stock traded as low as €6.94 ($7.80) and last traded at €7.04 ($7.91). 2,168,440 shares were traded during mid-day trading, an increase of 59% from the average session volume of 1,360,000 shares. The stock had previously closed at €7.29 ($8.19).

Evotec Stock Performance

The company has a market capitalization of $1.37 billion, a price-to-earnings ratio of -8.01, a P/E/G ratio of 0.98 and a beta of 1.05. The firm's 50 day simple moving average is €6.45 and its 200-day simple moving average is €7.74.

About Evotec

(Get Free Report)

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.

Featured Articles

Should You Invest $1,000 in Evotec Right Now?

Before you consider Evotec, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evotec wasn't on the list.

While Evotec currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress Is POURING Into This Stock
The Hottest AI Stock You Haven’t Bought Yet
This $13 Trillion Energy Breakthrough Will Make Millionaires

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines